PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT05158244
- Locations
- 🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT05156398
- Locations
- 🇺🇸
The Belinga Clinic, Fort Smith, Arkansas, United States
🇺🇸Advanced Investigative Medicine, Inc., Hawthorne, California, United States
🇺🇸Velocity Clinical Research San Diego, La Mesa, California, United States
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
- Conditions
- Breast Cancer Metastatic
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 847
- Registration Number
- NCT05155566
- Locations
- 🇦🇷
Pfizer country office, Buenos Aires, Argentina
🇬🇧Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK, Bollington, Chesshire, United Kingdom
Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan
- Conditions
- Breast Cancer
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1170
- Registration Number
- NCT05153187
- Locations
- 🇯🇵
Pfizer Japan Inc., Tokyo, Japan
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 245
- Registration Number
- NCT05145127
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Northwell Health HTC, New Hyde Park, New York, United States
🇺🇸Washington Institute for Coagulation d/b/a WACBD, Seattle, Washington, United States
Lorlatinib Continuation Study
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT05144997
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇨🇳The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT05141708
- Locations
- 🇺🇸
Pfizer Inc., New York, New York, United States
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
- Conditions
- Acute Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT05139615
- Locations
- 🇷🇸
Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
🇷🇸Clinical Center of Kragujevac, Kragujevac, Serbia
🇷🇸Healthcare Center Uzice, Užice, Serbia
This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05139680
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05132101
- Locations
- 🇰🇷
Pfizer Local Country Office, Seoul, Korea, Republic of